HOTH Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Hoth Therapeutics's net margin of 10.05%. Hoth Therapeutics's return on equity of -- beat Electromed's return on equity of 15.62%.

Hoth Therapeutics has a consensus price target of $4.50, signalling upside risk potential of 97.37%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 8.91%. Given that Hoth Therapeutics has higher upside potential than Electromed, analysts believe Hoth Therapeutics is more attractive than Electromed.

Hoth Therapeutics has a beta of 0.748, which suggesting that the stock is 25.197% less volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Hoth Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoth Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Hoth Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $14.7M. Hoth Therapeutics's net income of -$2.1M is lower than Electromed's net income of $1.5M. Notably, Hoth Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 42.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoth Therapeutics is -- versus 4.73x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Inspire Medical Systems has a net margin of -- compared to Hoth Therapeutics's net margin of 9.1%. Hoth Therapeutics's return on equity of -- beat Inspire Medical Systems's return on equity of 5.44%.

Hoth Therapeutics has a consensus price target of $4.50, signalling upside risk potential of 97.37%. On the other hand Inspire Medical Systems has an analysts' consensus of $239.60 which suggests that it could grow by 11.23%. Given that Hoth Therapeutics has higher upside potential than Inspire Medical Systems, analysts believe Hoth Therapeutics is more attractive than Inspire Medical Systems.

Hoth Therapeutics has a beta of 0.748, which suggesting that the stock is 25.197% less volatile than S&P 500. In comparison Inspire Medical Systems has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.768%.

Hoth Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoth Therapeutics pays -- of its earnings as a dividend. Inspire Medical Systems pays out -- of its earnings as a dividend.

Hoth Therapeutics quarterly revenues are --, which are smaller than Inspire Medical Systems quarterly revenues of $203.2M. Hoth Therapeutics's net income of -$2.1M is lower than Inspire Medical Systems's net income of $18.5M. Notably, Hoth Therapeutics's price-to-earnings ratio is -- while Inspire Medical Systems's PE ratio is 201.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoth Therapeutics is -- versus 8.57x for Inspire Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to Hoth Therapeutics's net margin of -10.5%. Hoth Therapeutics's return on equity of -- beat Myomo's return on equity of -84.04%.

Hoth Therapeutics has a consensus price target of $4.50, signalling upside risk potential of 97.37%. On the other hand Myomo has an analysts' consensus of -- which suggests that it could grow by 9.68%. Given that Hoth Therapeutics has higher upside potential than Myomo, analysts believe Hoth Therapeutics is more attractive than Myomo.

Hoth Therapeutics has a beta of 0.748, which suggesting that the stock is 25.197% less volatile than S&P 500. In comparison Myomo has a beta of 1.719, suggesting its more volatile than the S&P 500 by 71.909%.

Hoth Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoth Therapeutics pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Hoth Therapeutics quarterly revenues are --, which are smaller than Myomo quarterly revenues of $9.2M. Hoth Therapeutics's net income of -$2.1M is lower than Myomo's net income of -$966.4K. Notably, Hoth Therapeutics's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoth Therapeutics is -- versus 10.21x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Hoth Therapeutics's net margin of -17.98%. Hoth Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

Hoth Therapeutics has a consensus price target of $4.50, signalling upside risk potential of 97.37%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 345.55%. Given that Xtant Medical Holdings has higher upside potential than Hoth Therapeutics, analysts believe Xtant Medical Holdings is more attractive than Hoth Therapeutics.

Hoth Therapeutics has a beta of 0.748, which suggesting that the stock is 25.197% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Hoth Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoth Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Hoth Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Hoth Therapeutics's net income of -$2.1M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Hoth Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoth Therapeutics is -- versus 0.59x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.